(Q37278022)

19 August 2017

1 reference

title

B cells as therapeutic targets in autoimmune neurological disorders (English)

1 reference

19 August 2017

Marinos C Dalakas

1

1 reference

19 August 2017

23 September 2008

1 reference

Nature Clinical Practice Neurology

19 August 2017

1 reference

19 August 2017

4

1 reference

19 August 2017

10

1 reference

19 August 2017

557-567

1 reference

Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes

19 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

Distinct profiles of human B cell effector cytokines: a role in immune regulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

Determinants of Human B Cell Migration Across Brain Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

B lymphocytes as therapeutic targets in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

From T to B and back again: positive feedback in systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Invited article: inhibition of B cell functions: implications for neurology

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

B cells move to centre stage: novel opportunities for autoimmune disease treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

B cell immunobiology in disease: evolving concepts from the clinic

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Defective B cell tolerance checkpoints in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Regulatory roles for cytokine-producing B cells in infection and autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

An APRIL to remember: novel TNF ligands as therapeutic targets

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Molecules involved in T-B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Prospects for B-cell-targeted therapy in autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Multiple sclerosis--the plaque and its pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Identification of autoantibodies associated with myelin damage in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Acute transverse myelitis: is the "idiopathic" form vanishing?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Immunoglobulin and Complement Deposits in Nerves of Patients With Chronic Relapsing Polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Immune reactive C3d on the surface of myelin sheaths in neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Treatment of IgM antibody associated polyneuropathies using rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Treatment of stiff person syndrome with rituximab.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Duration of humoral immunity to common viral and vaccine antigens

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0901

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0901

1 reference

19 August 2017

1 reference

PubMed ID

18813230